Rigel Pharmaceuticals: Looking For More Growth
…
0,790$
-6,29%
Echtzeit-Aktienkurs Rigel Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Rigel Pharmaceuticals Inc. Aktie
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2024 Earnings Call Transcript
…
Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential
…
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2024 Earnings Call Transcript
…
Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy
…
Madrigal Pharmaceuticals wins FDA approval for liver disease drug; shares soar
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) shares soared after the biopharmaceutical firm revealed its live disease drug Rezdiffra has won US Food…
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Call Transcript
…
Rigel Pharmaceuticals: Gavreto Deal Expands Growth Prospects
…
Rigel Pharmaceuticals: Upgrading To A Top Idea Ahead Of Promising Q4/2023 Earnings Report
…
Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?
Rigel Pharmaceuticals (RIGL) Tavalisse tablet sales are expected to have risen in the fourth quarter, driven by demand growth.…
Heres Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now
Here, we discuss some reasons why buying Rigel Pharmaceuticals (RIGL) stock now may turn out to be a prudent move.…
Rigel Pharmaceuticals: Push To Profitability Continues, But COVID Beacon Seems Extinguished
…
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2023 Earnings Call Transcript
…
Rigel Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation
…
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 50% and 3.34%, respectively, for the quarter ended June 2023. Do the…
Rigel Pharmaceuticals GAAP EPS of -$0.04 beats by $0.04, revenue of $26.89M beats by $1.19M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rigel Pharmaceuticals Inc. Q2 Loss decreases, beats estimates
WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals Inc. (RIGL) announced Loss for second quarter that decreased from last year and beat the…
Rigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., July 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report…
Form 8-K RIGEL PHARMACEUTICALS For: May 25
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 11.11% and 7.32%, respectively, for the quarter ended March 2023. Do the…
Rigel Pharmaceuticals Inc. Q1 Loss decreases, beats estimates
WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals Inc. (RIGL) revealed Loss for first quarter that decreased from the same period last year…
Form 10-Q RIGEL PHARMACEUTICALS For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rigel Pharma begun at neutral at Piper Sandler on value creation potential
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rigel Pharmaceuticals (RIGL) Q4 Earnings and Revenues Surpass Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 114.29% and 36.56%, respectively, for the quarter ended December 2022. Do the…
Rigel Pharma, with beats on quarterly top and bottom lines, surges 19%
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rigel Pharmaceuticals Inc. Q4 Earnings Summary
WASHINGTON (dpa-AFX) - Below are the earnings highlights for Rigel Pharmaceuticals Inc. (RIGL):Earnings: $1.40 million in Q4 vs. -$22.64 million…
Form 8-K RIGEL PHARMACEUTICALS For: Mar 07
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-K RIGEL PHARMACEUTICALS For: Dec 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report…
Insiderhandel: CEO, President verkauft Aktien von Rigel Pharmaceuticals im Wert von 35.595$
Rodriguez, Raul R. - Vorstand - Tag der Transaktion: 2023-02-06...…
Rigel Pharmaceuticals Expects Q4 Revenue To Surge
WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL), a company focused on hematologic, cancer, and rare immune diseases, expects its fourth-quarter…
Rigel Pharmaceuticals Provides Business Update
REZLIDHIA™ U.S. FDA approval and commercial launch for the treatment of adult patients with relapsed or refractory AML with susceptible…
Form 8-K RIGEL PHARMACEUTICALS For: Jan 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Thinking about buying stock in 180 Life Sciences, HTG Molecular, Markforged, Icecure Medical, or Rigel Pharmaceuticals?
NEW YORK, Dec. 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATNF, HTGM, MKFG, ICCM, and RIGL. To…
Rigel Pharma Launches Rezlidhia In U.S. For Relapsed Acute Myeloid Leukemia With IDH1 Mutation
WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) announced the launch of Rezlidhia or olutasidenib capsules in the U.S. for the…
Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that REZLIDHIA™ (olutasidenib) capsules…
Thinking about buying stock in 180 Life Sciences, Viking Therapeutics, Camber Energy, New Oriental Education & Tech, or Rigel Pharmaceuticals?
NEW YORK, Dec. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATNF, VKTX, CEI, EDU, and RIGL. To…
Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes
R289 is an investigational, oral, inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), being studied as a potentially differentiated…
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Dec. 9, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has…
Thinking about buying stock in Rigel Pharmaceuticals, Mullen Automotive, COMSovereign, Credit Suisse, or Tilray?
NEW YORK, Dec. 2, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RIGL, MULN, COMS, CS, and TLRY. To…
Rigel Pharmaceuticals Shares Leap Premarket on FDA OK of Rezlidhia >RIGL
Rigel Pharmaceuticals Shares Leap Premarket on FDA OK of Rezlidhia >RIGL...…
Rigel stock soars after FDA approves leukemia treatment, 2 days after receiving delisting notice
Shares of Rigel Pharmaceuticals Inc. soared 39.5% in premarket trading Friday, after the biotechnology company announced Food and Drug…
XFRA : RI2A: Wiederaufnahme/Resumption
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…
Rigel: FDA Oks REZLIDHIA For Treatment Of R/R Acute Myeloid Leukemia With Susceptible IDH1 Mutation
WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals Inc. (RIGL) said that the U.S. Food and Drug Administration has approved REZLIDHIA or olutasidenib…
XFRA : RI2A: Aussetzung/Suspension
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME …
XFRA : INSTRUMENT_SUSPENSION - US7665596034
Instrument ID [10389] (RI2A - US7665596034) suspended...…
Form 8-K RIGEL PHARMACEUTICALS For: Nov 22
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Lags Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 1.56%, respectively, for the quarter ended September 2022. Do the…
Rigel Pharmaceuticals Inc. Q3 Loss decreases, beats estimates
WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals Inc. (RIGL) released Loss for third quarter that decreased from the same period last year…
Rigel Pharmaceuticals Q3 2022 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…